Podcast

Prof. Heerspink: DAPA-CKD and Use of Dapagliflozin

A podcast featuring the presenter of DAPA-CKD discussing results of the trial and how they inform use of dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes.

In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink, PhD, on dapagliflozin as a treatment in patients with chronic kidney disease.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology Congress 2020. The trial examined the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.

Related Videos
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
© 2025 MJH Life Sciences

All rights reserved.